➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Dow
Baxter
McKesson
Harvard Business School

Last Updated: May 11, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR INTRALIPID 10%

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Intralipid 10%

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00005889 Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion Unknown status Baylor College of Medicine N/A 1999-10-01 RATIONALE: Very low birth weight infants have problems maintaining normal blood sugar levels. Gluconeogenesis is the production of sugar from amino acids and fats. The best combination of amino acids, fat, and sugar to help very low birth weigh infants maintain normal blood sugar levels is not yet known. PURPOSE: Clinical trial to study how very low birth weight infants break down amino acids, fat, and sugar given by intravenous infusion, and the effect of different combinations of nutrients on the infants' ability to maintain normal blood sugar levels.
NCT00005889 Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion Unknown status National Center for Research Resources (NCRR) N/A 1999-10-01 RATIONALE: Very low birth weight infants have problems maintaining normal blood sugar levels. Gluconeogenesis is the production of sugar from amino acids and fats. The best combination of amino acids, fat, and sugar to help very low birth weigh infants maintain normal blood sugar levels is not yet known. PURPOSE: Clinical trial to study how very low birth weight infants break down amino acids, fat, and sugar given by intravenous infusion, and the effect of different combinations of nutrients on the infants' ability to maintain normal blood sugar levels.
NCT00048646 Progesterone Treatment of Blunt Traumatic Brain Injury Completed National Institute of Neurological Disorders and Stroke (NINDS) Phase 1/Phase 2 2002-05-01 The purpose of this study is to determine if progesterone treatment safely reduces brain swelling and damage after injury.
NCT00048646 Progesterone Treatment of Blunt Traumatic Brain Injury Completed David Wright Phase 1/Phase 2 2002-05-01 The purpose of this study is to determine if progesterone treatment safely reduces brain swelling and damage after injury.
NCT00074477 Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 2 2003-10-01 The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate injection compared to placebo in the treatment of the symptoms of schizophrenia in adults. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.
NCT00088647 Study Evaluating MST-997 in Advanced Malignant Solid Tumors Terminated Wyeth is now a wholly owned subsidiary of Pfizer Phase 1 1969-12-31 The primary objective of this clinical research study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of intravenous (IV) MST-997 formulated in Intralipid 20% administered on a weekly schedule to subjects with advanced malignant solid tumors.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Intralipid 10%

Condition Name

Condition Name for Intralipid 10%
Intervention Trials
Parenteral Nutrition 6
Obesity 5
Hypertension 5
Cholestasis 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Intralipid 10%
Intervention Trials
Insulin Resistance 10
Cholestasis 8
Liver Diseases 6
Infertility 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Intralipid 10%

Trials by Country

Trials by Country for Intralipid 10%
Location Trials
United States 65
Canada 14
Egypt 7
France 4
Netherlands 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Intralipid 10%
Location Trials
Texas 7
Ohio 5
New York 5
Georgia 5
Massachusetts 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Intralipid 10%

Clinical Trial Phase

Clinical Trial Phase for Intralipid 10%
Clinical Trial Phase Trials
Phase 4 25
Phase 3 11
Phase 2/Phase 3 7
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Intralipid 10%
Clinical Trial Phase Trials
Completed 28
Recruiting 16
Not yet recruiting 13
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Intralipid 10%

Sponsor Name

Sponsor Name for Intralipid 10%
Sponsor Trials
Emory University 5
Fresenius Kabi 5
Baxter Healthcare Corporation 4
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Intralipid 10%
Sponsor Trials
Other 80
Industry 21
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Boehringer Ingelheim
Harvard Business School
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.